WeedMD Inc. (TSXV:WMD) (“WeedMD” or the “Company”), a federally-licensed producer and distributor of medical cannabis, is pleased to announce that the Company has appointed Dr. Jonas Vanderzwan as Medical Director and Chair of its Clinical Advisory Board. The Clinical Advisory Board will oversee all areas related to WeedMD’s medical research and development initiatives.

“We are honoured to have Dr. Vanderzwan join WeedMD. This is a strategic and important appointment for our patient base who are seeking standardized treatment options and more precise strain selection and dosing from their medical practitioner,” said Bruce Dawson-Scully, CEO, WeedMD. “An obstacle for many cannabis patients is the limited information coming from the medical community about cannabis use for specific ailments. Dr. Vanderzwan brings a wealth of experience, knowledge and the willingness to support patients and medical practitioners. He will also be participating in studies alongside leading institutions and their researchers from around the world.”


Dr. Vanderzwan is a physician with more than 15 years of primary care experience, and recently served as the lead physician of a London, Ontario based medical cannabis patient assessment clinic. Recognized in Southwestern Ontario as a cannabis educator and specialist, he has been actively providing medical staff with guidance on cannabis prescribing protocols, cannabis pharmacology, physiological effects and assessment tools. Dr. Vanderzwan is assisting with the establishment of an interest group at the Ontario Medical Association (OMA) with the purpose of continued advocacy and promotion of cannabis. He is also a member of the International Cannabinoid Research Society (ICRS), Canadian Consortium for the Investigation of Cannabinoids (CCIC), and International Association for Cannabinoid Medicines (IACM).

“As an enthusiastic proponent of prescribing medical cannabis as an alternative treatment option for patients, I’m pleased to be joining WeedMD – a licensed producer that takes great pride in its commitment to providing patients with responsible and innovative products and therapies – as well as encouraging sound practices in the seniors’ community,” said Dr. Vanderzwan. “While it is important that all the players in the cannabis industry take an active role in public education, it is also integral that we promote funding initiatives that aim to further establish cannabis as a legitimate medicine and WeedMD is actively pursuing such initiatives.”

WeedMD is committed to establishing credibility for cannabis in the medical community, and is in the process of securing a Health Canada Dealer’s License [read here].  A Dealer’s License will allow the Company to conduct R&D activities, store cannabis derivatives, process natural health products and export cannabis oils and concentrates to international markets.

About WeedMD Inc.

WeedMD Inc. is the publicly-traded parent company of WeedMD Rx Inc., a federally-licensed producer and distributor of medical cannabis and cannabis oil under the Access to Cannabis for Medical Purposes Regulations (“ACMPR”). The Company operates a 26,000 sq. ft. indoor facility in Aylmer, Ontario, and is awaiting its second-site cultivation license for its greenhouse facility located in Strathroy, Ontario, representing 610,000 sq. ft. or 14 acres under glass. WeedMD has entered into supply agreements in addition to strategic relationships with established cannabis brands.

The Company is focused on providing medical cannabis to the seniors’ market in Canada through its specialized and comprehensive platform. It is dedicated to educating healthcare practitioners and furthering public understanding of the role that medical cannabis plays – including as it pertains to regulatory requirements, indications and potential side effects.

For more information, access our investor presentation here and corporate video here.

Follow WeedMD:

Facebook: https://www.facebook.com/weedmd/
LinkedIn: https://www.linkedin.com/company-beta/5020743/
Twitter: https://twitter.com/WeedMD
Instagram: https://www.instagram.com/weedmd/

For further information, please contact:

WeedMD Inc.

Keith Merker, Chief Financial Officer
Tel: 519-765-2440 Ext. 222
Email: investor@weedmd.com

To learn more, visit us at www.weedmd.com

For Media Inquiries:

Marianella delaBarrera
Margin Communications & Public Relations
Tel: 416-897-6644
Email: marianella@marginpr.com

Forward-Looking Information

This press release contains forward-looking information based on current expectations. Statements about the date of trading of the Company’s common shares on the Exchange and final regulatory approvals, among others, are forward-looking information. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. The Company assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by law.

___________________________________________________________________________________________________________________________________________
NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE

Click here to connect with WeedMD Inc. and receive an Investor’s Presentation.

Source: globenewswire.com

The Israeli cannabis market is picking up with a new supply deal from a Canadian producer.

Also this week, new data showed sales of Canadian cannabis edible products may be stalling.

Keep reading... Show less

The Israeli cannabis market is picking up as a Canadian producer announced a new supply deal in the country.

Also this week it was shown the sales of Canadian cannabis edible products may be stalling, according to new data.

Keep reading... Show less

The Portnoy Law Firm advises investors that class action lawsuits have been filed on behalf of investors in the following publicly traded companies. Shareholders interested in taking an active role in these cases have until the deadlines indicated below to petition the court. There is no cost or obligation to you. See below for more information on these cases.

Credit Acceptance Corporation investors (NASDAQ: CACC); December 1, 2020 deadline, click here to join .

Keep reading... Show less
  • On November 19 , the Mexican Senate passed comprehensive adult-use cannabis legalization, moving Mexico towards becoming one of the few countries to legalize cannabis nationally
  • On March 31, 2020 , the Company entered into an agreement with Tecnologico de Monterrey , the leading university in Mexico , to educate physicians across Latin America , in advance of the impending regulations in Mexico
  • To date, close to 550 LatAm physicians have obtained their diploma accrediting completion of Khiron’s medical education program
  • The Company plans to deploy its ZereniaTM medical cannabis clinics and telehealth strategy in Mexico , building on the success of its vertical integration strategy in Colombia
  • Expanding the Zerenia clinic strategy will build on the Company’s Colombia knowledge and proven distribution capabilities, with rapid telehealth service adoption and over 5,600 medical cannabis scripts filled to date
  • Mexico represents one of the largest potential markets for medical cannabis in the world and is anticipated to reach $1.2bn USD by 2028 (Prohibition Partners).
  • Company to release Q3 2020 financials and host webcast on Tuesday, December 1st

Khiron Life Sciences Corp. (“Khiron” or the “Company”) (TSXV: KHRN ), (OTCQX: KHRNF), ( Frankfurt : A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe welcomes the passing of adult-use cannabis legislation by the Mexican Senate, which moves the country closer to a legalized cannabis market, and towards provision for medical cannabis products.  Khiron has had a presence in Mexico since 2018 and has been working with doctors and medical institutions to develop a deep understanding of the market.

Keep reading... Show less

Recap of special management call includes upcoming corporate milestones and details of proposed combination with established beverage manufacturer

Emerging leader in infused cannabis beverages, BevCanna Enterprises Inc. (CSE:BEV, OTCQB:BVNNF, FSE:7BC) (“BevCanna” or the “Company”) is pleased to provide a recorded recap of the special management call held on Tuesday November 24, 2020. The call discussed upcoming corporate milestones and reviewed recent developments at the developer and manufacturer of cannabinoid‐infused beverages and consumer products for in‐house brands and white label clients.

Keep reading... Show less